Science & Enterprise subscription

Follow us on Twitter

  • Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences li… https://t.co/WGboSsrf7U
    about 16 hours ago
  • New post on Science and Enterprise: Gene Therapy Company Exploring DNA Circuit Technology https://t.co/2YUM4DVZRK #Science #Business
    about 16 hours ago
  • A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects again… https://t.co/3JtSqD1Sa2
    about 20 hours ago
  • New post on Science and Enterprise: Vaccine Stops Lyme Bacteria in Preclinical Test https://t.co/7H0Lc90nRe #Science #Business
    about 20 hours ago
  • Stop the panic porn ... Coronavirus Variants Don’t Have to Be Scary. Still, Mask Up. https://t.co/d6aDu2Ucj6
    about 23 hours ago

Please share Science & Enterprise

NIH Funds $24 Million for Genetic Links to Alzheimer’s

(NIST.gov)

8 July 2014. National Institutes of Health is awarding $24 million to eight academic medical centers for research on genomic factors behind people developing or avoiding Alzheimer’s disease. Recipients of the four-year grants are Boston University, Case Western Reserve University in Cleveland, Columbia University in New York, University of Miami, University of . . . → Read More: NIH Funds $24 Million for Genetic Links to Alzheimer’s

MRI Helps Screen Alzheimer’s, Brain Degeneration Dementia

(National Institute of Mental Health)

Medical researchers at University of Pennsylvania in Philadelphia developed an algorithm based on magnetic resonance imaging (MRI) to differentiate cases of Alzheimer’s disease from front temporal lobe degeneration, which has similar dementia symptoms. The findings from the research team led by postdoctoral fellow and first author Corey McMillan . . . → Read More: MRI Helps Screen Alzheimer’s, Brain Degeneration Dementia

U.S. Alzheimer’s Patient Implanted with Deep Brain Pacemaker

(National Institute of Mental Health)

A patient in the early stages of Alzheimer’s disease at Johns Hopkins medical center in Baltimore received an implanted deep-brain stimulation device, the first such surgery in the U.S. The implant is part of a clinical trial testing the deep brain stimulation device for Alzheimer’s disease patients made . . . → Read More: U.S. Alzheimer’s Patient Implanted with Deep Brain Pacemaker

Bristol-Myers Squibb, Biotech Partner on Alzheimer’s Test

(National Institute of Mental Health)

Opko Health Inc., a biotechnology company in Miami, Florida, said today it has a collaboration agreement with the drug manufacturer Bristol-Myers Squibb Company for Opko’s diagnostic test technology. Opko’s blood tests are being developed from its technology that identifies biomarkers for a range of diseases including neurodegenerative disorders.

. . . → Read More: Bristol-Myers Squibb, Biotech Partner on Alzheimer’s Test

Alectos Therapeutics, Merck Collaborate on Alzheimer’s Drug

Alectos Therapeutics Inc. in Burnaby, British Columbia, Canada will collaborate with global pharmaceutical company Merck & Co. to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme believed to be involved in the development of Alzheimer’s disease and other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop, and . . . → Read More: Alectos Therapeutics, Merck Collaborate on Alzheimer’s Drug